Arizona is bringing back its iconic 'cactus' logo to the McKale Center floor, and asking fans exactly how to do so. The school produced four images of what the court could look like, all of which ...

The global medical flexible packaging market size is projected to be valued at USD 20.22 billion in 2024 and reach USD 27.72 billion by 2030, growing at a CAGR of 5.4% according to a new report by The ...

Public and political opinion is shifting in favour of nuclear power. There is a growing acceptance that nuclear energy is needed to provide reliable, clean and abundant energy to power our ...

a health sciences professor at SFU and the Pfizer/Heart & Stroke Foundation Chair in Cardiovascular Prevention Research. "The world extends beyond high-income countries when we think about ...

Pfizer Ltd has reported an 85% jump in net profit at ₹330.94 crore in the fourth quarter ended March 2025, boosted by a gain in exceptional item from completion of asset sale and transfer.

which has been largely attributed to smaller biotechnologies taking their own drugs to market rather than relying on investments from larger companies like Pfizer. Some key biotechnology ...

Pfizer plans to manufacture the drug substance for SSGJ-707 in Sanford, North Carolina, and the drug product in McPherson, Kansas. The company said it also plans to make a $100 million equity ...

May 19 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), opens new tab, paying $1.25 billion upfront ...

(Reuters) -U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental ...

(Reuters) -U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones ...

(Reuters) -Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug ...

Pfizer is wagering billions of dollars on a new kind of cancer immunotherapy, agreeing Monday to license a type of dual-targeting medicine that’s emerged as a must-have for drugmakers in oncology. The ...